The RNA Pol II elongation factor Ell3 marks enhancers in ES cells and primes future gene activation
about
Enhancers: five essential questionsSMC complexes link gene expression and genome architectureThe Mediator complex: a central integrator of transcriptionChromatin features and the epigenetic regulation of pluripotency states in ESCsComparative annotation of functional regions in the human genome using epigenomic dataA permissive chromatin state regulated by ZFP281-AFF3 in controlling the imprinted Meg3 polycistronTEG-1 CD2BP2 controls miRNA levels by regulating miRISC stability in C. elegans and human cellsEll3 stimulates 5-FU resistance in a breast cancer cell line.Inflammation-induced repression of chromatin bound by the transcription factor Foxp3 in regulatory T cellsMechanisms and models of somatic cell reprogramming.Looping back to leap forward: transcription enters a new eraAF9 YEATS domain links histone acetylation to DOT1L-mediated H3K79 methylationSystematic integration of RNA-Seq statistical algorithms for accurate detection of differential gene expression patterns.Stably paused genes revealed through inhibition of transcription initiation by the TFIIH inhibitor triptolideThe pluripotent regulatory circuitry connecting promoters to their long-range interacting elements.Gene target specificity of the Super Elongation Complex (SEC) family: how HIV-1 Tat employs selected SEC members to activate viral transcription.Genome-wide detection of DNase I hypersensitive sites in single cells and FFPE tissue samples.Effect of Interaction between Chromatin Loops on Cell-to-Cell Variability in Gene ExpressionDynamic enhancer-gene body contacts during transcription elongation.Regulation of the imprinted Dlk1-Dio3 locus by allele-specific enhancer activityMechanisms underlying the formation of induced pluripotent stem cells.RNA polymerase II pausing as a context-dependent reader of the genome.Ell3 stabilizes p53 following CDDP treatment via its effects on ubiquitin-dependent and -independent proteasomal degradation pathways in breast cancer cellsTranscriptional elongation checkpoint control in development and diseaseComprehensive analysis of promoter-proximal RNA polymerase II pausing across mammalian cell types.NIPBL Controls RNA Biogenesis to Prevent Activation of the Stress Kinase PKR.In silico identification of enhancers on the basis of a combination of transcription factor binding motif occurrencesZic2 is an enhancer-binding factor required for embryonic stem cell specification.Enhancer biology and enhanceropathies.Ready, pause, go: regulation of RNA polymerase II pausing and release by cellular signaling pathwaysDecoding transcriptional enhancers: Evolving from annotation to functional interpretationRegulation of RNA polymerase II-mediated transcriptional elongation: Implications in human disease.T-bet Activates Th1 Genes through Mediator and the Super Elongation Complex.Enhancers reside in a unique epigenetic environment during early zebrafish development.ELL inhibits E2F1 transcriptional activity by enhancing E2F1 deacetylation via recruitment of histone deacetylase 1.A transcriptional complex composed of ER(α), GATA3, FOXA1 and ELL3 regulates IL-20 expression in breast cancer cells.The free-energy cost of interaction between DNA loops.Ell3 Modulates the Wound Healing Activity of Conditioned Medium of Adipose-derived Stem Cells.Combinatorial effects of multiple enhancer variants in linkage disequilibrium dictate levels of gene expression to confer susceptibility to common traits.Selective expression of the transcription elongation factor ELL3 in B cells prior to ELL2 drives proliferation and survival.
P2860
Q22121999-2FB9ABD0-971E-4360-891C-D7EE13BDA890Q26826804-11EDBC1F-9C62-4A2E-8175-57F26341B7F1Q26849595-D2AE955C-753D-44BE-8B10-9ACAD7C25F14Q26860693-02FA3F04-8C42-450B-A2FD-00072BA813A9Q30597594-4695108E-22A3-4CCF-BDEA-AF5BC89E2B91Q33554080-91E8A5E0-D387-42FD-8C3E-A2FAE44A9360Q33554213-B8219970-6115-49A7-8F22-3AADF235BB5FQ33750730-68AF68EB-10B9-4720-AB07-35C3087FC15DQ33954755-C13574C1-FAB6-4A73-B782-ABC1CE0DB253Q34345169-1D5FB86A-DE8E-466A-8231-9FF073EC2FF0Q34412648-33B79D59-751D-4134-947B-A4FE7F8CE3DDQ34449085-7AD072F3-071E-4077-BD7A-AE3F8D0AE434Q34450998-62B9369D-CAB9-4E15-8130-9EE1B37F75D6Q34799963-CE4C0A6F-3F98-4ED1-B5DD-02B48EB25883Q35573905-BD5CDF4C-682D-435D-B8A1-4BB106495124Q35842547-1909E27C-23F0-47D2-9DE7-658622832CC1Q35852065-A5F42ED1-6BEC-46CB-BCD8-B2BEEC103F0EQ36010921-DCD08872-DA4A-43E0-8381-D8DE1AFD8C1EQ36158104-C29DFC1D-F080-4B87-AD62-04D30D1B155DQ36432067-01919C9E-C262-46A9-B9E3-89067EEC7583Q36469676-FDB83F75-E613-4AD2-9033-8D73E46868C3Q36505626-41F5A9F4-E075-4382-845E-019EB1F24282Q36689029-74EDF393-0478-490F-BCA5-A68F2E1D6262Q36902905-529522CF-56E4-4F89-9E06-86DFA9D8AE28Q36969299-72B222A8-6CC0-4665-B8E3-F436E4F53C0DQ36997282-BC1D4DE9-7F84-47AB-993D-0496B45D8DADQ37223613-0C8E1270-4382-4290-8EB0-5CAC7EEF38DAQ37228941-53744F6E-F55E-4C9A-BA87-49AA232B0868Q38193691-48E4B8CB-0341-489A-B8E7-EDAD83012A85Q38562823-FEF3E982-9919-4E31-82F6-CC83ABFC13F5Q38844237-785F6671-CA37-4826-A77E-E2DA20AF3369Q38912988-667FF4C8-78A7-46A0-A223-096246766BDCQ39689800-F229331A-7FFC-4F54-B45C-30DD9B3BE787Q41905395-3F75911F-1E39-42E9-810C-BB055386A939Q41908759-6775FEED-3A64-47BE-A9BC-E2ADF1816713Q42028260-7FA8974C-1B3F-4059-8BB6-D3268EF4AC91Q42282508-B205DC73-6A18-44FA-B7D0-1B9F410B4131Q42653926-DB2A3B4A-DE86-4461-BA6B-17CCD25817ADQ42770081-AEC5E5A8-D722-4CA9-A3DB-AEE6A60DA601Q47876829-5FD53625-AC75-4BC5-8C5B-F33F627278D5
P2860
The RNA Pol II elongation factor Ell3 marks enhancers in ES cells and primes future gene activation
description
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2013
@ast
im Januar 2013 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2013/01/17)
@sk
vědecký článek publikovaný v roce 2013
@cs
wetenschappelijk artikel (gepubliceerd op 2013/01/17)
@nl
наукова стаття, опублікована в січні 2013
@uk
مقالة علمية (نشرت في 17-1-2013)
@ar
name
The RNA Pol II elongation fact ...... primes future gene activation
@ast
The RNA Pol II elongation fact ...... primes future gene activation
@en
The RNA Pol II elongation fact ...... primes future gene activation
@nl
type
label
The RNA Pol II elongation fact ...... primes future gene activation
@ast
The RNA Pol II elongation fact ...... primes future gene activation
@en
The RNA Pol II elongation fact ...... primes future gene activation
@nl
prefLabel
The RNA Pol II elongation fact ...... primes future gene activation
@ast
The RNA Pol II elongation fact ...... primes future gene activation
@en
The RNA Pol II elongation fact ...... primes future gene activation
@nl
P2093
P2860
P3181
P1433
P1476
The RNA Pol II elongation fact ...... primes future gene activation
@en
P2093
Alexander S. Garruss
Ali Shilatifard
Chengqi Lin
Fengli Guo
Zhuojuan Luo
P2860
P304
P3181
P356
10.1016/J.CELL.2012.12.015
P407
P577
2013-01-17T00:00:00Z